Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Lucie Heinzerling(University of St.Gallen), Jason J. Luke(UPMC Hillman Cancer Center)
Cited by 510
Related Papers
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
|PLoS ONE|2013|470
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
|Journal of Clinical Oncology|2021|220
Tumor cell p38 inhibition to overcome immunotherapy resistance
|Research Square|2023|5